Investor Presentaiton
CASE STUDIES: INVESTMENT PROJECTS IN 2018-2019
Association
AEB
of European
Businesses
By launching full cycle insulin production in Russia, the company moves to
the production of modern insulins in pre-filled disposable FlexPenⓇ. Pre-
filled injection-pens, which account for more than 89% of the volume of
insulin analogues 1,2 in Russia, are the most common type of insulin delivery
devices worldwide¹,2.
At the moment, Novo Nordisk is a Russian producer, which fully meets the
objectives of localization of production, stipulated by the completed Phar-
ma-2020 strategy and new Pharma-2030 strategy being developed by the
Government.
"We decided to localize production in Russia for many reasons, said Mike
Doustdar, Novo Nordisk A/S Executive vice president, International Op-
erations, in his interview to Rossiyskaya Gazeta (Nº225 (7688)). First,
we are working in the country for which, unfortunately, diabetes is a big
problem. In Russia, about 10 million people suffer from this disease, and
half of them do not even know about it. Developing business in countries
with burden of diabetes, we always indicate our willingness to work here
for a long time. Of course, localization of production is the best evidence of
such willingness.
The second reason is that our company's intentions and commitments to
support Russian patients clearly coincided with what the Russian Govern-
ment expected from multi-national companies. This is primarily an interest
in foreign direct investment, in response to which Government provides
certain benefits, which was reflected in Pharma-2020 program. Therefore,
from a competitive point of view, it was important for us to take advantage
of this opportunity."
1. http://zakupki.gov.ru
2. IMS Health database, ATC Class 4,
MAT Sep 2017 version
3. Письмо Минпромторга
Nº32428/07 OT 27.05.2016
цикла инсулинов
диск
Калужская
область
HOBO
Дил
nova
ЗАПУСК
7View entire presentation